forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss GLP-1 Receptor Agonist Market Growth

Wilmington, DE, May 01, 2026 (GLOBE NEWSWIRE) -- Compounded semaglutide and tirzepatide are not FDA-approved finished drug products and have not been evaluated by the FDA for safety, effectiveness, or quality

But Indian bodies, diets, and health patterns are different

Yet selenium's therapeutic range is narrow: deficiency undermines neuroendocrine function, while chronic excess can provoke selenosis with neurological symptoms of its own (139)

Mounjaro is administered once weekly via subcutaneous injection, offering convenience and effectiveness for patients with type 2 diabetes

Noronha JC, Braunschweig CL, Gracey E, et al

For FY27, the report estimates an incremental revenue opportunity of 1,0002,000 crore in Indias branded formulations market, 4,500 crore in regulated markets such as Canada and Brazil, and 500-1,000 crore in emerging markets